Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Linagliptin/Metformin FDC vs Single Agents
NCT02220647Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jan 2010
- Primary completion
- Apr 2010
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of linagliptin and metformin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Area under the concentration-time curve of linagliptin in plasma over the time interval from 0 to 72 h, Maximum measured concentration of the analyte in plasma up to 72 hours and 1 more. Started Jan 2010; status: completed.
02
Drugs
linagliptinmetformin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02220647.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02220647.